EvaluatePharma’s 10 best-selling drugs in 2026 and their expected global sales:
- Keytruda (Merck) — $24.9 billion
- Opdivo (Bristol Myers Squibb) — $12.7 billion
- Eliquis (Bristol Myers Squibb) — $12.6 billion
- Biktarvy (Gilead) — $11.7 billion
- Imbruvica (AbbVie + Johnson & Johnson) — $10.7 billion
- Ibrance (Pfizer) — $9.7 billion
- Tagrisso (AstraZeneca) — $9.5 billion
- Dupixent (Sanofi) — $9.4 billion
- Trikafta (Vertex Pharmaceuticals) —$8.7 billion
- Ozempic (Novo Nordisk) — $8.3 billion
More articles on pharmacy:
Walgreens CEO steps down
AstraZeneca, Daiichi Sankyo partner in $6B cancer drug deal
Trump signs 4 executive orders targeting drug prices: 6 things to know
